Welcome to our dedicated page for Black Titan SEC filings (Ticker: BTTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Black Titan Corporation's SEC filings document its foreign private issuer reporting through Form 6-K current reports and related press-release exhibits. The disclosures center on the launch of cryptocurrency-related business activities, the Digital Asset Treasury Plus strategy, digital asset industry updates and capital-structure matters tied to convertible-note financing.
The filing record also includes governance and reporting matters, including an approved change in independent registered public accounting firm, audit-committee action and internal-control disclosures. Other material-event disclosures cover shareholder voting, security-structure and regulatory topics relevant to the company's public-company status.
Black Titan Corporation is registering up to 5,917,484 ordinary shares for resale by existing shareholders. These consist of 2,344,100 shares issued as merger consideration, 1,474,530 shares issuable upon conversion of Series A preferred shares, 176,470 shares from Series C preferred conversion, 9,563 shares including 6,250 underlying options for a director, 512,820 shares issued under an October 30, 2025 settlement, and 1,400,001 shares to be issued to three advisory service providers.
The company will not receive proceeds from resale of these shares, other than any cash paid if the 6,250 options are exercised. Those options have exercise prices of $30.40 and $26.20 per share, while the ordinary share price was $2.75 on December 12, 2025, so the prospectus notes exercises are currently unlikely. As of the prospectus date, 9,086,610 ordinary shares were outstanding, trading on Nasdaq under the symbol “BTTC.”
Black Titan, a Cayman Islands company, was formed in 2024 and completed a business combination on October 1, 2025, acquiring Titan Pharmaceuticals, Inc. and Malaysian HCM software distributor TalenTec. The prospectus cautions that resale of this substantial block of shares, or expectations of such sales, could increase volatility or lead to a significant decline in the trading price.